These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 20071369)

  • 1. When and why to start antiretroviral therapy?
    Gatell JM
    J Antimicrob Chemother; 2010 Mar; 65(3):383-5. PubMed ID: 20071369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.
    Simcock M; Blasko M; Karrer U; Bertisch B; Pless M; Blumer L; Vora S; Robinson JO; Bernasconi E; Terziroli B; Moirandat-Rytz S; Furrer H; Hirschel B; Vernazza P; Sendi P; Rickenbach M; Bucher HC; Battegay M; Koller MT;
    Antivir Ther; 2007; 12(6):931-9. PubMed ID: 17926647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.
    Wolbers M; Battegay M; Hirschel B; Furrer H; Cavassini M; Hasse B; Vernazza PL; Bernasconi E; Kaufmann G; Bucher HC;
    Antivir Ther; 2007; 12(6):889-97. PubMed ID: 17926643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
    Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
    Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
    HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E
    Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When to start antiretroviral therapy: a swinging pendulum?
    Gallant JE
    Top HIV Med; 2008; 16(2):82-8. PubMed ID: 18591715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
    Sullivan PS; Hanson DL; Teshale EH; Wotring LL; Brooks JT
    AIDS; 2006 May; 20(8):1171-9. PubMed ID: 16691069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
    Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early antiretroviral therapy: the role of cohorts.
    Sabin CA
    Curr Opin HIV AIDS; 2009 May; 4(3):200-5. PubMed ID: 19532051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 subtypes and response to combination antiretroviral therapy in Europe.
    Bannister WP; Ruiz L; Loveday C; Vella S; Zilmer K; Kjaer J; Knysz B; Phillips AN; Mocroft A;
    Antivir Ther; 2006; 11(6):707-15. PubMed ID: 17310815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvements in antiretroviral therapy outcomes over calendar time.
    Boyd MA
    Curr Opin HIV AIDS; 2009 May; 4(3):194-9. PubMed ID: 19532050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Revised guideline "Antiretroviral Treatment"].
    Werkgroep antiretrovirale behandeling van de Nederlandse Vereniging van Aids Behandelaren
    Ned Tijdschr Geneeskd; 2005 Oct; 149(43):2399-405. PubMed ID: 16277129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Patients co-infected with HIV and hepatitis-B virus (HBV): the favourable effect of lamivudine, as part of combined antiretroviral therapy, on HBV may be dependent upon the number of CD4-cells].
    Smit MC; Haverkamp MH; Weersink AJ; Boucher CA; Hoepelman IM
    Ned Tijdschr Geneeskd; 2004 Nov; 148(47):2330-4. PubMed ID: 15587052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment.
    Kvale D; Ormaasen V; Kran AM; Johansson CC; Aukrust P; Aandahl EM; Frøland SS; Taskén K
    AIDS; 2006 Apr; 20(6):813-20. PubMed ID: 16549964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.
    Mocroft A; Phillips AN; Ledergerber B; Katlama C; Chiesi A; Goebel FD; Knysz B; Antunes F; Reiss P; Lundgren JD
    AIDS; 2006 May; 20(8):1141-50. PubMed ID: 16691065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.